Purpose: In this study, we aimed to evaluate the efficacy of peribulbar triamcinolone injections to treat inflammatory signs of Graves' ophthalmopathy (GO) in patients with moderate to severe GO and associated optic neuropathy (ON).
Methods: Twenty-one patients with active GO [clinical activity score (CAS) > or = 4] and systemic thyroid disease under control were enrolled in this prospective pilot study. Peribulbar triamcinolone acetonide was injected in each orbit (42 eyes), in four doses of 20 mg at 2-week intervals. Ophthalmological examination including CAS evaluation, visual field, computerized tomography (CT) scan and digital photography were performed before and after treatment.
Results: Twenty-one patients (11 with moderate disease, 10 with ON) were enrolled in this study and followed for at least 14 months. Initial mean CAS was 6.38 +/- 1.49, which dropped to 1.8 +/- 1.12 after 6 months of treatment (P = 0.01; mean difference of 4.57 +/- 1.56; range 1-8 score points). ON was diagnosed in 10 patients. Of these, 66% improved with peribulbar triamcinolone exclusively. A transitory increase in intraocular pressure in two patients was controlled with topic medication.
Conclusion: Peribulbar triamcinolone injections reduce the inflammatory signs of moderate GO, as measured by the CAS, and could also be used as an alternative treatment for ON. Randomized clinical trials are needed to compare the results of triamcinolone peribulbar injections to those of other treatment modalities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1755-3768.2008.01171.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-altitude retinopathy and retinal hemorrhage: A case report.
Medicine (Baltimore)
November 2024
Department of Ophthalmology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- High-altitude retinopathy (HAR) is a vision-threatening condition caused by low oxygen levels at high altitudes, which may sometimes resolve on its own without symptoms.
- A 41-year-old man experienced vision loss after rapidly ascending to high altitude, leading to diagnoses of HAR following thorough ophthalmic evaluations revealing serious eye issues.
- Treatment included injections and medications to enhance eye health, and after 4 months, he showed improvement, emphasizing the importance of leaving high altitudes promptly to prevent long-term vision damage.
Central Retinal Artery Occlusion after Peribulbar Injection of Triamcinolone Acetonide in Thyroid-associated Ophthalmopathy.
J Craniofac Surg
July 2024
Department of Ophthalmology, Mianyang Central Hospital, Sichuan Province, China.
Central retinal artery occlusion (CRAO) is a form of acute ocular ischemic syndrome that causes visual loss. Timely treatment is of great importance for visual recovery, but the prognosis is usually poor. By analyzing the pathogenesis, diagnosis, and treatment process of a CRAO case after peribulbar injection of triamcinolone acetonide in thyroid-associated ophthalmopathy (TAO), this study aims to investigate the association of CRAO with hemodynamics and orbital pressure, thereby providing references in safety improvement of diagnosis and treatment on TAO.
View Article and Find Full Text PDFFluocinolone intravitreal implant (Iluvien) for macular edema secondary to immune recovery uveitis in patient with acute myeloid leukemia.
J Ophthalmic Inflamm Infect
May 2024
Department of Ophthalmology, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain.
Purpose: To report the use of Fluocinolone intravitreal implant (Iluvien) for the treatment of persistent cystoid macular edema (CME) due to immune recovery uveitis syndrome in a patient with previous cytomegalovirus retinitis and acute myeloid leukemia.
Design: Case report.
Methods: The clinical history of a patient who received an Iluvien implant in one eye for the treatment of cystoid macular edema due to immune recovery uveitis syndrome, previously treated with peribulbar Triamcinolone and intravitreal Dexamethasone injections, was reviewed.
Peribulbar Corticosteroids for Ocular Myasthenia Gravis.
J Neuroophthalmol
September 2024
Department of Developmental Biology and Cancer Research (RL), The Hebrew University-Hadassah Medical School, Jerusalem, Israel; and Departments of Neurology (MG) and Ophthalmology (JMK), Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Background: Ocular myasthenia gravis is treated predominantly by oral medications, with the potential for systemic adverse effects. Successful treatment has been achieved using peribulbar dexamethasone. We assessed the effect of peribulbar dexamethasone or triamcinolone (40-mg Triesence), a longer-acting corticosteroid, targeting the peribulbar area as opposed to directly injecting the affected extraocular muscle.
View Article and Find Full Text PDFA controlled clinical study on efficacy and safety of periocular triamcinolone acetonide injection for treating ocular myasthenia gravis.
BMC Ophthalmol
January 2024
Department of Opthalmology, Aier Eye Hospital of Wuhan University, No. 481, Zhongshan Road, Wuchang District, Wuhan, 430060, China.
Article Synopsis
- The study evaluates the effectiveness and safety of peribulbar triamcinolone acetonide injections for treating ocular myasthenia gravis (OMG) compared to traditional oral therapies.
- 22 OMG patients received the injections and showed significant reductions in symptoms, such as ptosis and ophthalmoplegia, after 4 weeks of treatment.
- While the injection resulted in better minimal manifestations status (MMS) than oral therapy, further research is needed to evaluate its long-term effectiveness and safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!